- Home
- RLYB vs CVKD Comparison
RLYB vs CVKD Comparison
Compare RLYB & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- CVKD
- Stock Information
- Founded
- RLYB 2018
- CVKD 2022
- Country
- RLYB United States
- CVKD United States
- Employees
- RLYB N/A
- CVKD N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- RLYB Health Care
- CVKD Health Care
- Exchange
- RLYB Nasdaq
- CVKD Nasdaq
- Market Cap
- RLYB 24.1M
- CVKD 27.0M
- IPO Year
- RLYB 2021
- CVKD 2023
- Fundamental
- Price
- RLYB $0.61
- CVKD $14.13
- Analyst Decision
- RLYB Hold
- CVKD Strong Buy
- Analyst Count
- RLYB 2
- CVKD 1
- Target Price
- RLYB N/A
- CVKD $32.00
- AVG Volume (30 Days)
- RLYB 290.8K
- CVKD 25.8K
- Earning Date
- RLYB 11-07-2025
- CVKD 11-07-2025
- Dividend Yield
- RLYB N/A
- CVKD N/A
- EPS Growth
- RLYB N/A
- CVKD N/A
- EPS
- RLYB N/A
- CVKD N/A
- Revenue
- RLYB $761,000.00
- CVKD N/A
- Revenue This Year
- RLYB N/A
- CVKD N/A
- Revenue Next Year
- RLYB N/A
- CVKD N/A
- P/E Ratio
- RLYB N/A
- CVKD N/A
- Revenue Growth
- RLYB 154.51
- CVKD N/A
- 52 Week Low
- RLYB $0.22
- CVKD $8.74
- 52 Week High
- RLYB $1.24
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- RLYB 61.83
- CVKD 54.38
- Support Level
- RLYB $0.54
- CVKD $12.11
- Resistance Level
- RLYB $0.57
- CVKD $14.35
- Average True Range (ATR)
- RLYB 0.04
- CVKD 0.66
- MACD
- RLYB 0.01
- CVKD -0.08
- Stochastic Oscillator
- RLYB 93.92
- CVKD 76.99
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.